120 related articles for article (PubMed ID: 37258312)
1. Surgical debulking is associated with improved survival for patients with neuroendocrine liver metastases of unknown primary.
Ruff SM; Thompson DA; Lad NL; Anantha S; DePeralta DK; Weiss MJ; Deutsch GB
HPB (Oxford); 2023 Sep; 25(9):1074-1082. PubMed ID: 37258312
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy.
Ammann M; Gudmundsdottir H; Hackl H; Antwi SKA; Santol J; Habermann EB; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Nagorney DM; Cleary SP; Halfdanarson TR; Starlinger PP
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38717544
[TBL] [Abstract][Full Text] [Related]
3. Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: A systematic review and meta-analysis.
Kulkarni R; Kabir I; Hodson J; Raza S; Shah T; Pandanaboyana S; Dasari BVM
Ann Hepatobiliary Pancreat Surg; 2022 Feb; 26(1):31-39. PubMed ID: 34980681
[TBL] [Abstract][Full Text] [Related]
4. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.
Katz SC; Donkor C; Glasgow K; Pillarisetty VG; Gönen M; Espat NJ; Klimstra DS; D'Angelica MI; Allen PJ; Jarnagin W; Dematteo RP; Brennan MF; Tang LH
HPB (Oxford); 2010 Dec; 12(10):674-83. PubMed ID: 21083792
[TBL] [Abstract][Full Text] [Related]
5. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?
Wang YZ; Chauhan A; Rau J; Diebold AE; Opoku-Boateng A; Ramcharan T; Boudreaux JP; Woltering EA
Chin Clin Oncol; 2016 Feb; 5(1):4. PubMed ID: 26932428
[TBL] [Abstract][Full Text] [Related]
7. Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.
Gudmundsdottir H; Habermann EB; Vierkant RA; Starlinger P; Thiels CA; Warner SG; Smoot RL; Truty MJ; Kendrick ML; Halfdanarson TR; Nagorney DM; Cleary SP
Ann Surg Oncol; 2023 Aug; 30(8):4840-4851. PubMed ID: 37208566
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
[TBL] [Abstract][Full Text] [Related]
9. Histopathological growth patterns of neuroendocrine tumor liver metastases.
Meyer Y; Bohlok A; Olthof P; Donckier V; Doukas M; Lucidi V; Vermeulen P; Grünhagen D; Verhoef C
Clin Exp Metastasis; 2023 Jun; 40(3):227-234. PubMed ID: 37183203
[TBL] [Abstract][Full Text] [Related]
10. Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases.
Mahuron KM; Singh G
J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048539
[TBL] [Abstract][Full Text] [Related]
11. Surgical Management of Neuroendocrine Tumor Liver Metastases.
Tran CG; Sherman SK; Chandrasekharan C; Howe JR
Surg Oncol Clin N Am; 2021 Jan; 30(1):39-55. PubMed ID: 33220808
[TBL] [Abstract][Full Text] [Related]
12. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis.
Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM
HPB (Oxford); 2018 Mar; 20(3):277-284. PubMed ID: 28964630
[TBL] [Abstract][Full Text] [Related]
14. Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases.
Lee FT; Williams J; Nordgren R; Schwarz JL; Setia N; Roggin K; Polite B; Rangrass G; Liao CY; Millis JM; Keutgen XM
Am J Surg; 2024 Mar; 229():17-23. PubMed ID: 37802701
[TBL] [Abstract][Full Text] [Related]
15. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.
Morgan RE; Pommier SJ; Pommier RF
Surgery; 2018 Jan; 163(1):218-225. PubMed ID: 29103583
[TBL] [Abstract][Full Text] [Related]
16. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
[TBL] [Abstract][Full Text] [Related]
17. Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors: A retrospective study.
Jiao X; Luan W; Peng X; Liu L; Zhang L; Zhou L
Medicine (Baltimore); 2020 Dec; 99(51):e23655. PubMed ID: 33371100
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for unresectable neuroendocrine liver metastases.
John BJ; Davidson BR
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):357-69. PubMed ID: 22646257
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
[TBL] [Abstract][Full Text] [Related]
20. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
